Rapport Therapeutics partners with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China. $20M upfront + up to $308M milestones and tiered royalties for epilepsy & bipolar treatment.
Wells Fargo analyst rates Rapport Therapeutics as Overweight with $43 target, citing strong Phase 2a seizure data and promising efficacy.
RAP-219 shows amazing Phase 2a results for drug-resistant focal seizures: 77.8% seizure reduction & 24% seizure-free! This precision medicine, targeting TARPγ8, is well-tolerated & moves to Phase 3, offering new hope. Also eyed for bipolar mania & pain.
